Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Not for human or veterinary application
In a 68- and 72-week clinical trial studying Wegovy (2.4 mg), brand-name Semaglutide, and Zepbound (15 mg), brand-name Tirzepatide, in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20% respectively, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
Price: We included products available at a variety of price points, without compromising on quality
Get in touch with Womize , select your region, and begin under our franchise model
Understanding the potential indirect mechanismsincluding rapid weight loss, electrolyte disturbances, and dehydrationcan help patients and clinicians manage these symptoms effectively
US$ 24.06
US$ 25.94
US$ 20.49
US$ 23.93
US$ 29.92
US$ 29.59
US$ 25.38
